The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Will Be The Estimated Market Size Of The Oncology Based In-Vivo CRO Market By 2030?
The oncology based in-vivo CRO market has experienced significant expansion in recent years. This market is projected to grow from $1.5 billion in 2025 to $1.66 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.6%. Historically, this growth was influenced by factors such as the increasing demand for preclinical oncology studies, the development of animal model-based research, the rising prevalence of blood cancers and solid tumors, the global expansion of contract research organizations, and more stringent regulatory requirements for preclinical validation.
The oncology based in-vivo cro market size is anticipated to experience substantial expansion in the coming years. This market is projected to reach $2.54 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.2%. This growth during the forecast period is fueled by an intensified focus on patient-derived xenograft models, the growing incorporation of digital data management systems, advancements in personalized oncology drug development, an increase in the outsourcing of in-vivo studies to expert CROs, and the wider uptake of automated imaging and monitoring solutions. Significant trends expected during this period include the increased adoption of digital platforms for managing in-vivo studies, the expanding application of AI and machine learning in preclinical oncology research, the broader deployment of genomic profiling for patient-derived xenograft models, increased automation in in-vivo testing and data analysis processes, and the rising implementation of IoT-enabled systems for monitoring laboratory equipment and study outcomes.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp
What Core Drivers Are Transforming The Oncology Based In-Vivo CRO Market?
The increasing incidence of cancer is projected to stimulate expansion within the oncology-based in-vivo CRO market in the future. Cancer encompasses a range of illnesses characterized by the uncontrolled division of atypical cells, which extend beyond their typical limits, can emerge in virtually any organ or tissue, and disseminate throughout the body via the blood and lymphatic systems. Effective cancer treatment and diagnosis necessitate novel drugs and devices, all of which must pass through various preclinical trials, clinical trials, and regulatory approvals prior to commercialization. An oncology in-vivo-based CRO is a firm engaged by a sponsoring entity to deliver research support, including executing full or partial stages of a preclinical in-vivo study (involving testing with living organisms like animals, plants, or whole cells) before a drug or device proceeds to human trials. Consequently, the rising prevalence of cancer has fueled a greater need for innovative treatments and therapies, thereby propelling the expansion of the oncology-based in-vivo CRO market. As an illustration, in April 2024, the American Cancer Society, a US-based non-profit organization, reported approximately 609,000 cancer-related deaths and 1.9 million new cancer cases in the country in 2022. Projections indicate an estimated 620,000 cancer deaths for 2024, suggesting a slight rise in mortality rates. The growing prevalence of cancer is fueling the oncology-based in-vitro CRO market.
Which Segment Groups Define The Oncology Based In-Vivo CRO Market Landscape?
The oncology based in-vivo cro market covered in this report is segmented –
1) By Indication: Blood Cancer, Solid Tumors, Other Indications
2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models
3) By Application: Pharmaceutical Companies Or Biopharma, Biotechnology Companies, Academic And Research Institutes, CROs Or Contract Research Partners
Subsegments:
1) By Blood Cancer: Leukemia, Lymphoma, Myeloma
2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas
What Trends Are Affecting The Oncology Based In-Vivo CRO Market Dynamics?
Major companies in the oncology ablation market are developing innovative products, such as advanced ablation systems that offer improved precision, integrated imaging technologies for real-time guidance, and enhanced safety features. Advanced ablation systems with improved precision refer to medical devices that utilize sophisticated technology to accurately target and eliminate abnormal tissue, including tumors, while minimizing damage to surrounding healthy tissue. For instance, in March 2024, Medtronic Plc, an Ireland-based medical equipment manufacturing company, secured US Food and Drug Administration approval for its OsteoCool 2.0 bone tumor ablation system, which is designed to treat painful bone metastases and benign tumors like osteoid osteoma. This upgraded system boasts significant enhancements, including the capability to simultaneously use four internally cooled probes, enabling the ablation of two vertebral bodies at once or the creation of larger ablation zones in non-spinal applications.
Which Organizations Are Operating Within The Oncology Based In-Vivo CRO Market?
Major companies operating in the oncology based in-vivo cro market are Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, Shanghai Medicilon Inc., Pharmalegacy Laboratories, Oncotest GmbH, Biocytogen LLC
Access The Complete Oncology Based In-Vivo CRO Market Report:
https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report
Which Region Holds The Largest Share In The Oncology Based In-Vivo CRO Market?
North America was the largest region in the oncology-based in-vivo CRO market in 2025.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Oncology Based In-Vivo CRO Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=10521&type=smp
Browse Through More Reports Similar to the Global Oncology Based In-Vivo CRO Market 2026, By The Business Research Company
Specialty Foods Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/specialty-foods-global-market-report
Community Oncology Services Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report
Oncology Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model